A Post-Market Study in Greece of a Minimally Invasive Breast Lift Procedure Utilizing the Renuvion APR System

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

April 26, 2024

Study Completion Date

April 26, 2024

Conditions
Breast Ptosis
Interventions
DEVICE

Renuvion APR System

"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."

Trial Locations (1)

15562

Metropolitan General Hospital, Athens

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Apyx Medical

INDUSTRY

NCT05665335 - A Post-Market Study in Greece of a Minimally Invasive Breast Lift Procedure Utilizing the Renuvion APR System | Biotech Hunter | Biotech Hunter